IPP Bureau

GSK acquires oligonucleotide drug startup Elsie
GSK acquires oligonucleotide drug startup Elsie

By IPP Bureau - June 08, 2024

Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need

Briefs: Concord Biotech and Shelter Pharma
Briefs: Concord Biotech and Shelter Pharma

By IPP Bureau - June 08, 2024

Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs

Lupin completes acquisition of two brands from Sanofi in Europe and Canada
Lupin completes acquisition of two brands from Sanofi in Europe and Canada

By IPP Bureau - June 08, 2024

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas

Indoco Remedies receives tentative ANDA approval for Canagliflozin, Metformin Hydrochloride Tablets
Indoco Remedies receives tentative ANDA approval for Canagliflozin, Metformin Hydrochloride Tablets

By IPP Bureau - June 07, 2024

Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus

Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam
Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam

By IPP Bureau - June 07, 2024

DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable

Torrent inks licensing agreement with Takeda to commercialize its novel gastrointestinal drug in India
Torrent inks licensing agreement with Takeda to commercialize its novel gastrointestinal drug in India

By IPP Bureau - June 07, 2024

Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders

Merck completes € 180 million investment to expand Schnelldorf Distribution Center
Merck completes € 180 million investment to expand Schnelldorf Distribution Center

By IPP Bureau - June 07, 2024

Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany

AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer
AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer

By IPP Bureau - June 07, 2024

PICCOLO trial met its primary endpoint of objective response rate (ORR)

Health Ministry and Defence Ministry ink MoU to set up dedicated Tele MANAS cell for armed forces
Health Ministry and Defence Ministry ink MoU to set up dedicated Tele MANAS cell for armed forces

By IPP Bureau - June 06, 2024

The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country

Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer
Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

By IPP Bureau - June 06, 2024

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response

Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA
Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA

By IPP Bureau - June 06, 2024

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process

GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation
GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation

By IPP Bureau - June 06, 2024

Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims

Bayer and Samsung take action against sleep disturbances associated with menopause
Bayer and Samsung take action against sleep disturbances associated with menopause

By IPP Bureau - June 06, 2024

Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life

Melissa Seymour to join Lilly as executive vice president of Global Quality
Melissa Seymour to join Lilly as executive vice president of Global Quality

By IPP Bureau - June 06, 2024

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry

Melissa Seymour to join Lilly as executive vice president of Global Quality
Melissa Seymour to join Lilly as executive vice president of Global Quality

By IPP Bureau - June 06, 2024

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry

Latest Stories

Interviews

Packaging